ArticlePathogens (Basel, Switzerland)2023
An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women.
Article in Pathogens (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 24 citations in OpenAlex.
- UropathogenicAntibiotics (Basel, Switzerland) · 2026Review
- Recurrent Urinary Tract Infections in Women: Current Management Guidelines and Therapeutic Options.Cureus · 2026Review
- Effectiveness of Individualized Autovaccine Immunotherapy in Women With Recurrent Urinary Tract Infections: A Prospective Cohort Study.Open forum infectious diseases · 2026Article
- The sublingual vaccine MV140 is dominant over prophylactic antibiotics for the prevention of recurrent, uncomplicated urinary tract infections in adult women A cost-utility analysis.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Article
- From Awareness to Action: Women's Self-Care Strategies and Clinical Behaviors in Recurrent Urinary Tract Infections.Medicina (Kaunas, Lithuania) · 2026Article
- More than an infection: the ecological puzzle of recurrent urinary tract infections.Frontiers in cellular and infection microbiology · 2026Review
- Harnessing pro-inflammatory and immunopathologic immune responses in urinary tract infections for vaccine development: it's all about a balance.Frontiers in immunology · 2026Review
- Current Evidence on Safety, Efficacy and Efficiency of Sublingual Vaccine UromunePathogens (Basel, Switzerland) · 2025Review
- The Central Importance of Vaccines to Mitigate the Threat of Antibiotic-Resistant Bacterial Pathogens.Vaccines · 2025Review
- Antibiotic therapy for treating overactive bladder is not supported by clinical evidence.Nature reviews. Urology · 2025Review
- Prevalence of recurrent urinary tract infections and its associated factors in female staff of reproductive age group in a medical college in central Kerala: a cross-sectional study.BMC infectious diseases · 2025Article
- Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics.Nature reviews. Microbiology · 2025Review
- Structure-based design of an immunogenic, conformationally stabilized FimH antigen for a urinary tract infection vaccine.PLoS pathogens · 2025Article
- Autovaccine immunoprophylaxis in patients with neurogenic bladder experiencing recurrent urinary tract infections.Frontiers in immunology · 2025Article
- Immunoprophylaxis with MV140 Is Effective in the Reduction of Urinary Tract Infections-A Prospective Real-Life Study.Vaccines · 2024Article
- A cynomolgus monkeyInfection and immunity · 2024Article
- MV140 Mucosal Vaccine Induces Targeted Immune Response for Enhanced Clearance of UropathogenicVaccines · 2024Article
- Secondary Analysis of Interstitial Cystitis/Bladder Pain Syndrome Patients Enrolled in a Recurrent Urinary Tract Infection Prevention Study Provides a Novel Paradigm for Etio-Pathogenesis and Practical Management of This Infection Phenotype.Pathogens (Basel, Switzerland) · 2024Article
- Photochemical inactivation as an alternative method to produce a whole-cell vaccine for uropathogenicMicrobiology spectrum · 2024Article
- It's uncomplicated: Prevention of urinary tract infections in an era of increasing antibiotic resistance.PLoS pathogens · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Uncomplicated recurrent urinary tract infections (rUTIs) in women are associated with episodic bothersome symptoms and have a significant impact on the mental and physical quality of life. Treatment with antibiotics (short- and long-term dosing) results in acute and chronic side effects and costs and promotes general antibiotic resistance. Improved nonantibiotic management of rUTI in women represents a true, unmet medical need. MV140 is a novel sublingual mucosal-based bacterial vaccine developed for the prevention of rUTI in women. Based on observational, prospective, and randomized placebo-controlled studies, MV140 has been shown to safely prevent (or reduce the risk of) UTIs, reduce antibiotic use, overall management costs, and patient burden while improving the overall quality of life in women suffering from rUTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.